Skip to main content
SCYX
NASDAQ Life Sciences

SCYNEXIS Q2: Cash Runway Into 2029, Phase 1 Data for Kidney Disease Drug Due Q3

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$5.27
Mkt Cap
$51.191M
52W Low
$3.53
52W High
$10.48
52W Position info
49% above low
Off High info
50% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

SCYX sits 49% above its 52-week low of $3.53 on light trading volume (0.4× avg).

Summary

SCYNEXIS reported Q2 results with a strengthened balance sheet—$71.1M in cash, runway into 2029—and multiple near-term catalysts. The company swung to a profit due to a $14.2M warrant liability gain. The Phase 1 study of SCY-770, its AMPK activator for ADPKD, is underway with topline data expected this quarter; Phase 2 is on track for Q4. Dosing completed in the IV SCY-247 antifungal study, also with Q3 data readout. R&D spending dropped 46% to $3.9M. The GSK partnership for BREXAFEMME could yield up to $146M in annual milestones. With a $51M market cap, the cash position and upcoming data readouts materially de-risk the story.

At the time of this announcement, SCYX was trading at $5.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.2M. The 52-week trading range was $3.53 to $10.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

SCYX - Latest Insights

SCYX
Nov 05, 2026, 8:01 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.84
Real-time Price: $2.82 info
Change: -$1.02 (-27%) info
Market Cap: $28.068M info
SCYX
Oct 06, 2026, 7:53 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.18
Real-time Price: $2.82 info
Change: -$2.36 (-46%) info
Market Cap: $28.068M info
SCYX
Sep 28, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.71
Real-time Price: $2.82 info
Change: -$1.89 (-40%) info
Market Cap: $28.068M info
SCYX
Sep 28, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $6.46
Real-time Price: $2.82 info
Change: -$3.64 (-56%) info
Market Cap: $28.068M info
SCYX
Aug 10, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.16
Real-time Price: $2.82 info
Change: -$2.34 (-45%) info
Market Cap: $28.068M info